Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 4/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL511496 | 0.77 | LMNA (0.41) | MAOBNPC1RAB9AALDH1A1HPGD | |
| SCHEMBL5542643 | 0.76 | NOTUM (0.40) | CA12CA9MAPT | |
| SCHEMBL511213 | 0.76 | PDE4A (0.59) | MAOBNPC1RAB9AALDH1A1MAPT | |
| SCHEMBL511124 | 0.72 | KDM4E (0.38) | MAOBNQO2NPC1RAB9AALDH1A1 | |
| SCHEMBL5324357 | 0.72 | ESR1 (0.43) | CA12CA1CA2CA9CA14 | |
| SCHEMBL3608419 | 0.72 | GAA (0.41) | MAOBNQO2NPC1RAB9AALDH1A1 | |
| SCHEMBL1711875 | 0.72 | CA1 (0.44) | EGFRCA12CA1CA2CA7 | |
| SCHEMBL9151672 | 0.69 | CA1 (0.79) | CA12CA1CA2CA7CA9 | |
| SCHEMBL197522 | 0.69 | CA1 (0.79) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6733562 | 0.69 | CA1 (0.79) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10174047-B2 | Thienodiazepine derivatives or pharmaceutically acceptable salts thereof, and pharmaceutical composition including the same as an active ingredient | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2019-01-08 | — | — | US | claimed |
| US-20180037589-A1 | THIENODIAZEPINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2018-02-08 | — | — | US | claimed |
| US-9540348-B2 | Imidazole-1-yl pyrimidine derivatives, or pharmacutically acceptable salt thereof, and pharmaceutic composition comprising the same as an active ingredient | INDUSTRYUNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2017-01-10 | — | — | US | claimed |
| US-20160200706-A1 | Imidazole-1-yl pyrimidine derivatives, or pharmacutically acceptable salt thereof, and pharmaceutic composition comprising the same as an active ingredient | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2016-07-14 | — | — | US | claimed |
| EP-2421852-B9 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITOR | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-01 | — | — | EP | claimed |
| US-8815839-B2 | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2014-08-26 | — | — | US | claimed |
| EP-2421852-B1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITOR | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-21 | — | — | EP | claimed |
| US-20130184251-A1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-07-18 | — | — | US | claimed |
| US-8415341-B2 | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-04-09 | — | — | US | claimed |
| EP-2421852-A1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITOR | Janssen Pharmaceutica N.V. (BE) | 2012-02-29 | — | — | EP | claimed |
| US-20100324015-A1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | claimed |
| WO-2010124121-A1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITOR | JANSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | claimed |
| EP-1257265-B1 | USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS | BIOAGENCY AG (DE) | 2004-01-21 | — | — | EP | claimed |
| US-20030036532-A1 | Use of 2-phenylene diamine derivatives for the treatment of infections | JOMAA PHARMAKA GMBH (DE) | 2003-02-20 | — | — | US | claimed |
| EP-1257265-A2 | USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS | Jomaa Pharmaka GmbH (DE) | 2002-11-20 | — | — | EP | claimed |
| WO-2001070026-A2 | 2-PHENYLENEDIAMINE DERIVATIVES AS HERBICIDES | JOMAA PHARMAKA GMBH (DE) | 2001-09-27 | — | — | WO | claimed |
| WO-2001062709-A2 | USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS | JOMAA PHARMAKA GMBH (DE) | 2001-08-30 | — | — | WO | claimed |
| US-6083945-A | USEFUL IN TREATING HUMANS OR OTHER MAMMALS WITH CARDIAC ARRHYTHMIA AND/OR CARDIAC FIBRILLATION | THE PROCTER & GAMBLE COMPANY (US) | 2000-07-04 | — | — | US | claimed |
| US-5691369-A | CARDIOVASCULAR DISORDERS | THE PROCTOR & GAMBLE COMPANY (US) | 1997-11-25 | — | — | US | claimed |
| US-10174047-B2 | Thienodiazepine derivatives or pharmaceutically acceptable salts thereof, and pharmaceutical composition including the same as an active ingredient | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2019-01-08 | — | — | US | disclosed |
| US-20180037589-A1 | THIENODIAZEPINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2018-02-08 | — | — | US | disclosed |
| US-9540348-B2 | Imidazole-1-yl pyrimidine derivatives, or pharmacutically acceptable salt thereof, and pharmaceutic composition comprising the same as an active ingredient | INDUSTRYUNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2017-01-10 | — | — | US | disclosed |
| WO-2016137060-A1 | THIENODIAZEPINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | 한양대학교 에리카산학협력단 | 2016-09-01 | — | — | WO | disclosed |
| US-20160200706-A1 | Imidazole-1-yl pyrimidine derivatives, or pharmacutically acceptable salt thereof, and pharmaceutic composition comprising the same as an active ingredient | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2016-07-14 | — | — | US | disclosed |
| EP-2421852-B9 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITOR | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-01 | — | — | EP | disclosed |
| US-8815839-B2 | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2014-08-26 | — | — | US | disclosed |
| EP-2421852-B1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITOR | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-21 | — | — | EP | disclosed |
| US-8586770-B2 | Unsaturated steroid compounds | Harbor Therapeutics, Inc. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20130184251-A1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-07-18 | — | — | US | disclosed |
| US-8415341-B2 | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-04-09 | — | — | US | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| EP-2421852-A1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITOR | Janssen Pharmaceutica N.V. (BE) | 2012-02-29 | — | — | EP | disclosed |
| US-20120029260-A1 | Screening and Treatment Method | BIOVIE INC. | 2012-02-02 | — | — | US | disclosed |
| US-8093400-B2 | Compounds useful in therapy | PFIZER INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20110137057-A1 | Unsaturated Steroid Compounds | BIOVIE INC. | 2011-06-09 | — | — | US | disclosed |
| US-20110085984-A1 | Drug Product and Process for Making | BIOVIE INC. | 2011-04-14 | — | — | US | disclosed |
| US-7910755-B2 | Stem cell expansion and uses | HARBOR BIOSCIENCES, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| US-20100324015-A1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | disclosed |
| US-20100317652-A1 | Compounds Useful In Therapy | PFIZER INC | 2010-12-16 | — | — | US | disclosed |
| WO-2010124121-A1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITOR | JANSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
| US-7745630-B2 | Triazolyl piperidine arginine vasopressin receptor modulators | BRYANS JUSTIN STEPHEN | 2010-06-29 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| EP-1807118-A2 | STEROID ANALOGS AND CHARACTERIZATION AND TREATMENT METHODS | Hollis-Eden Pharmaceuticals Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| US-20070077203-A1 | Surrogate markers | BIOVIE INC. | 2007-04-05 | — | — | US | disclosed |
| US-20070077201-A1 | Stem cell expansion and uses | BIOVIE INC. | 2007-04-05 | — | — | US | disclosed |
| WO-2007030124-A2 | TREATMENT SCREENING METHODS | HOLLIS-EDEN PHARMACEUTICALS, INC (US) | 2007-03-15 | — | — | WO | disclosed |
| US-20070053832-A1 | Drug product and process for making | BIOVIE INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070014719-A1 | Steroid analogs and characterization and treatment methods | BIOVIE INC. | 2007-01-18 | — | — | US | disclosed |
| CN-1898244-A | Triazole derivatives as vasopressin antagonists | PFIZER (US) | 2007-01-17 | — | — | CN | disclosed |
| WO-2006110172-A2 | STEROID ANALOGS AND CHARACTERIZATION AND TREATMENT METHODS | HOLLIS-EDEN PHARMACEUTICALS.INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| US-20060088473-A1 | Treatment screening methods | BIOVIE INC. | 2006-04-27 | — | — | US | disclosed |
| US-20060073099-A1 | Treatment screening methods | BIOVIE INC. | 2006-04-06 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-20050154024-A1 | Compounds useful in therapy | PFIZER INC | 2005-07-14 | — | — | US | disclosed |
| EP-1257265-B1 | USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS | BIOAGENCY AG (DE) | 2004-01-21 | — | — | EP | disclosed |
| US-20030036532-A1 | Use of 2-phenylene diamine derivatives for the treatment of infections | JOMAA PHARMAKA GMBH (DE) | 2003-02-20 | — | — | US | disclosed |
| EP-1257265-A2 | USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS | Jomaa Pharmaka GmbH (DE) | 2002-11-20 | — | — | EP | disclosed |
| EP-0598061-B1 | NOVEL 4-OXOCYCLIC UREAS USEFUL AS ANTIARRHYTHMIC AND ANTIFIBRILLATORY AGENTS | PROCTER & GAMBLE PHARMA (US) | 2002-07-17 | — | — | EP | disclosed |
| WO-2001070026-A2 | 2-PHENYLENEDIAMINE DERIVATIVES AS HERBICIDES | JOMAA PHARMAKA GMBH (DE) | 2001-09-27 | — | — | WO | disclosed |
| WO-2001062709-A2 | USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS | JOMAA PHARMAKA GMBH (DE) | 2001-08-30 | — | — | WO | disclosed |
| US-5994354-A | Cyclic urethanes useful as antiarrhythmic and antifibrillatory agents | THE PROCTER & GAMBLE COMPANY (US) | 1999-11-30 | — | — | US | disclosed |
| EP-0957103-A1 | Oxazolidinone derivatives useful as antiarrhythmic and antifibrillatory agents | Procter & Gamble Pharmaceuticals, Inc. (US) | 1999-11-17 | — | — | EP | disclosed |
| EP-0891976-A1 | Novel cyclic ureas useful as antiarrhythmic and antifibrillatory agents | PROCTER & GAMBLE PHARMACEUTICALS (US) | 1999-01-20 | — | — | EP | disclosed |
| US-5691369-A | CARDIOVASCULAR DISORDERS | THE PROCTOR & GAMBLE COMPANY (US) | 1997-11-25 | — | — | US | disclosed |
| US-5462940-A | 4-oxocyclic ureas useful as antiarrhythmic and antifibrillatory agents | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1995-10-31 | — | — | US | disclosed |
| EP-0599968-A1 | CYCLIC URETHANES USEFUL AS ANTIARRHYTHMIC AND ANTIFIBRILLATORY AGENTS | PROCTER & GAMBLE PHARMACEUTICALS (US) | 1994-06-08 | — | — | EP | disclosed |
| EP-0598046-A1 | NOVEL CYCLIC UREAS USEFUL AS ANTIARRHYTHMIC AND ANTIFIBRILLATORY AGENTS | PROCTER & GAMBLE PHARMACEUTICALS (US) | 1994-05-25 | — | — | EP | disclosed |
| EP-0598061-A1 | NOVEL 4-OXOCYCLIC UREAS USEFUL AS ANTIARRHYTHMIC AND ANTIFIBRILLATORY AGENTS | PROCTER & GAMBLE PHARMACEUTICALS (US) | 1994-05-25 | — | — | EP | disclosed |
| WO-1993004064-A1 | CYCLIC URETHANES USEFUL AS ANTIARRHYTHMIC AND ANTIFIBRILLATORY AGENTS | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1993-03-04 | — | — | WO | disclosed |
| WO-1993004064-A1 | CYCLIC URETHANES USEFUL AS ANTIARRHYTHMIC AND ANTIFIBRILLATORY AGENTS | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1993-03-04 | — | — | WO | disclosed |
| WO-1993004061-A1 | NOVEL 4-OXOCYCLIC UREAS USEFUL AS ANTIARRHYTHMIC AND ANTIFIBRILLATORY AGENTS | PROCTER & GAMBLE PHARMACEUTICALS (US) | 1993-03-04 | — | — | WO | disclosed |
| WO-1993004060-A1 | NOVEL CYCLIC UREAS USEFUL AS ANTIARRHYTHMIC AND ANTIFIBRILLATORY AGENTS | PROCTER & GAMBLE PHARMACEUTICALS (US) | 1993-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324015-A1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | MGLL, PNLIP, LIPC | EGFR 2662/4885CA12 4880/4885CA1 4879/4885 |
| US-20160200706-A1 | Imidazole-1-yl pyrimidine derivatives, or pharmacutically acceptable salt thereof, and pharmaceutic composition comprising the same as an active ingredient | BRAF, ARAF, NRAS | EGFR 370/4885CA12 4190/4885CA1 3564/4885 |
| US-20030036532-A1 | Use of 2-phenylene diamine derivatives for the treatment of infections | HRH2, ASPH, NQO2 | EGFR 1892/4885CA12 3630/4885CA1 4387/4885 |
| US-20060088473-A1 | Treatment screening methods | HSD3B1, HSD3B2, HSD17B11 | EGFR 3024/4885CA12 4028/4885CA1 4395/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | EGFR 3049/4885CA12 1998/4885CA1 3493/4885 |
| US-20180037589-A1 | THIENODIAZEPINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | RET, PDGFRB, FLT3 | EGFR 241/4885CA12 4675/4885CA1 4385/4885 |
| US-20070077203-A1 | Surrogate markers | TSG101, RAD50, DNASE1L3 | EGFR 1959/4885CA12 741/4885CA1 2789/4885 |
| US-20070014719-A1 | Steroid analogs and characterization and treatment methods | CYP17A1, HSD17B11, HSD3B1 | EGFR 3844/4885CA12 4338/4885CA1 4447/4885 |
| US-10174047-B2 | Thienodiazepine derivatives or pharmaceutically acceptable salts thereof, and pharmaceutical composition including the same as an active ingredient | PDGFRB, RET, PDGFRA | EGFR 176/4885CA12 4815/4885CA1 4586/4885 |
| US-20130184251-A1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | MGLL, PNLIP, LIPC | EGFR 2662/4885CA12 4880/4885CA1 4879/4885 |
| US-20110085984-A1 | Drug Product and Process for Making | CYP2D6, CYP3A5, CYP2B6 | EGFR 99/4885CA12 4385/4885CA1 4848/4885 |
| US-20050154024-A1 | Compounds useful in therapy | PTGER4, PTGER3, ALOX5 | EGFR 1080/4885CA12 4124/4885CA1 3885/4885 |
| US-20060073099-A1 | Treatment screening methods | HSD17B11, HSD3B2, HSD3B1 | EGFR 2901/4885CA12 3666/4885CA1 3804/4885 |
| US-20070053832-A1 | Drug product and process for making | CYP2D6, CYP3A5, CYP2B6 | EGFR 99/4885CA12 4385/4885CA1 4848/4885 |
| US-20100317652-A1 | Compounds Useful In Therapy | AVPR1A, AVPR1B, AVPR2 | EGFR 4801/4885CA12 3814/4885CA1 2197/4885 |
| US-20070077201-A1 | Stem cell expansion and uses | NES, CD44, FGF2 | EGFR 1165/4885CA12 2886/4885CA1 4049/4885 |
| US-20110137057-A1 | Unsaturated Steroid Compounds | SREBF1, SREBF2, NR1H3 | EGFR 3746/4885CA12 4711/4885CA1 4531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.